Dr. Valdes-Albini on the FDA Approval of Adjuvant Pertuzumab in HER2+ Breast Cancer

Frances Valdes-Albini, MD
Published: Thursday, Apr 12, 2018



Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

The data on adjuvant pertuzumab were presented at the 2018 ASCO Annual Meeting. The benefit seemed to be restricted to patients with node-positive disease. Therefore, pertuzumab in combination with trastuzumab (Herceptin) and chemotherapy should be considered as a treatment for patients with node-positive disease and perhaps in patients with hormone receptor-negative disease, states Valdes-Albini.

It will be interesting to see how this plays a role in patients who have received neoadjuvant therapy, says Valdes-Albini. A lot of physicians are offering dual blockade in the neoadjuvant setting, but the study doesn’t address the impact of adjuvant dual blockade in patients who have received neoadjuvant treatment.
 
SELECTED
LANGUAGE


Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

The data on adjuvant pertuzumab were presented at the 2018 ASCO Annual Meeting. The benefit seemed to be restricted to patients with node-positive disease. Therefore, pertuzumab in combination with trastuzumab (Herceptin) and chemotherapy should be considered as a treatment for patients with node-positive disease and perhaps in patients with hormone receptor-negative disease, states Valdes-Albini.

It will be interesting to see how this plays a role in patients who have received neoadjuvant therapy, says Valdes-Albini. A lot of physicians are offering dual blockade in the neoadjuvant setting, but the study doesn’t address the impact of adjuvant dual blockade in patients who have received neoadjuvant treatment.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x